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Abstract
Gemcitabine (dFdC) is an anti-cancer agent that is affected by cell cycle modulation. Staurosporine and 7-hydroxystauro-
sporine (UCN-01) are potent protein kinase C (PKC) inhibitors as well as inhibitors of cyclin dependent kinase 2 (cdk2) 
and were therefore investigated for potential synergism, cell cycle modulation, cell death induction, and the role of the p53 
protein. Lovo colon cancer cell line variants with wild type and mutant p53 (Lovo 175x2) or inactive (Lovo Li) were used 
for this purpose.  
Combinations of dFdC with staurosporine were most synergistic when cells were exposed to dFdC prior to staurosporine, 
while for UCN-01 the simultaneous exposure was most synergistic. This synergism appeared to be related with abrogation 
of the cell cycle and cell cycle proteins. For dFdC (1.0 μM), a gradual time dependent increase of cells in S phase (up to 
40%) was observed in all Lovo variants. Staurosporine (0.05 μM) initially induced accumulation of cells in the G2/M phase 
(after 24 hr), while 48 hr exposure showed accumulation in the S-phase. UCN-01 (0.5 μM) caused an arrest in G0/G1 after 
24 hr exposure, while after 48 hr cells accumulated in the S phase. Simultaneous exposure to dFdC combinations showed an 
average cell cycle distribution of both drugs when used alone. In sequential addition of dFdC combinations, the first drug 
dominated the cell cycle distribution. 
Synergism of gemcitabine combinations was associated with induction of cell death by UCN-01, which was 2-fold higher in 
Lovo 175x2 (mutant p53) compared to other Lovo variants. Additive effects in induction of cell death were observed at the 
simultaneous addition of dFdC and UCN-01, but exposure to dFdC prior to UCN-01 caused a 2-fold higher induction of 
cell death than the sum of each compound alone in Lovo 175x2 cells, in contrast to the other lines. Accumulation of cells in 
the G2/M phase prevented repair of DNA damage, resulting in increased apoptosis. These data demonstrate that staurospo-
rine and UCN-01 affect dFdC cytotoxicity via modulation of the cell cycle. 
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Introduction
Gemcitabine (dFdC) is widely used for treatment of solid 
tumors and almost always combined, either with cytototic 
drugs such as cisplatin, paclitaxel and 5-fluorouracil 
(5-FU) or targeted drugs such as erlotinib [1]. dFdC is a 
deoxynucleoside analogue, in which the 2’ hydrogens 
of the nucleoside deoxycytidine are replaced by fluoride. 
dFdC needs to be phosphorylated by deoxycytidine kinase 
(dCK) to become active. The main mechanism of action is 
incorporation of its active metabolite dFdC triphosphate 
(dFdCTP) into the DNA [2]. Furthermore, dFdC diphosphate 
(dFdCDP) inhibits ribonucleotide reductase (RNR), an 
essential enzyme that is involved in DNA synthesis [3]. 
RNR is responsible for the reduction of ribonucleotides 
to their corresponding deoxyribonucleotides that will be 
further phosphorylated to deoxynucleoside triphosphates 
(dNTPs). Inhibition of RNR is one of the self-potentiating 
properties of dFdC since this will lead to depletion of dNTP 
pools, increasing the dFdC incorporation into the DNA [4].
Combination therapies are rationally designed in order to 
increase the efficacy of the separate drugs and circumvent 
development of resistance. E.g. the combination of 
cisplatin and gemcitabine is based on a decreased repair 
of DNA-platinum adducts as well as an increased dFdC 
incorporation into DNA. Following preclinical data on the 
synergism of dFdC with cisplatin [5,6], this combination is 
now considered to be one of the most active schedules 
against NSCLC and bladder cancer [1,7].
Hence, increasing the efficacy of a combination will 
benefit most from the use of agents that work at different 
targets, inducing additive effects or ideally synergistic 
interactions. DNA damaging agents such as dFdC that 
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arrest cells in the S phase are suitable agents to be combined 
with cell cycle inhibitors that act on different cell cycle 
phases thereby increasing the therapeutic response. The 
protein kinase C (PKC) inhibitors staurosporine and its 
analogue UCN-01 are agents that  induce cell cycle arrest in 
preclinical experimentsts. Staurosporine is an indolo (2,3-
a) carbazole derived from bacterium Streptomyces which 
turned out to be a potent but non-selective inhibitor of PKC 
Staurosporine induces G1 [8] and G2 arrest [9] depending 
on the concentration [10,11]. Staurosporine is a potent 
inducer of cell death. [9,12]. Since staurosporine inhibits 
signal transduction pathways that regulate growth factor 
response, proliferation and apoptosis, and some preclinical 
results showed promising antitumor effects, new analogues 
were developed with higher selectivity for PKC, such as 
7-hydroxystaurosporine (UCN-01). UCN-01 exhibited a 
potent anti-tumor activity in both in vitro and in vivo tumor 
models [13]. Besides PKC inhibition, staurosporine and 
UCN-01 can affect kinases that are related to PKCs such 
as cyclin dependent kinases (cdks), which are involved 
in cell cycle progression. E.g. Kawakami demonstrated 
an inhibitory effect on cdks 2, 4 and 6 in NSCLC cell line 
A549 [14]. This decline increased levels of cdk inhibitors 
p27 and p21 members of the Cip/Kip family. Together 
with a decrease in cycline D3 levels with concomitant 
reduced phosphorylation of the retinoblastoma (Rb) gene 
all contribute to the induced G1 phase arrest by UCN-01 
[15,16,17]. UCN-01 also induces cell death in cell lines that 
lack p53 function while the induced cytotoxicity is p53 
independent [18,19].
In this study, we evaluated the combination of dFdC with 
staurosporine and UCN-01 focusing on growth inhibition, 
cell death induction, cell cycle and the role of the p53 
protein. Lovo colon cancer cell line variants with wild type 
(Lovo B2), non-functional (Lovo Li) and mutant (Lovo 175x2) 
p53 were used for this purpose. 
Materials and methods
Drugs and biochemicals
Dulbecco’s Modified Eagle’s Medium (DMEM) was 
obtained from Flow Laboratories (Irvine, Scotland). Both 
fetal calf serum (FCS) and Hank’s balanced salt solution 
(HBSS) were purchased from Gibco Europe (Paisly, UK). 
Gemcitabine (Gemzar, dFdC) was provided by Eli Lilly 
Research Laboratories, (Indianapolis, IN, USA), UCN-01 was 
kindly provided by  dr. Bob Schultz at the NCI (Bethesda, 
MD USA). Staurosporine and propidium iodide were from 
Sigma Chemical Co (St Louis, MO, UK). Hybond Enhanced 
ChemoLuminescence (ECL) nitrocellulose membranes, 
Hyperfilm ECL plus and ECL detection kit were obtained 
from Amersham International (Buckinghamshire, UK). Mouse 
monoclonal antibodies against human P53 (Clone Ab-2) 
and against E2F1 (clone KH-95) were from EMD Biosciences, 
Darmstadt, Germany, and from Santa Cruz Biotechnologies, 
respectively. The secondary antibody goat-anti-mouse 
was from DAKO (Glostrup, Denmark). Unless otherwise 
specified, all other chemicals were of analytical grade and 
commercially available. 
Cell lines
Lovo is a solid human colon cancer cell line. Lovo colon 
cancer cell line variants with wild type (Lovo B2), non-
functional (Lovo Li) and mutant (Lovo 175x2) p53 with 
a mutation at position 175 (Arg-His) leading to gain of 
function [20] were grown as monolayers and were cultured 
in DMEM medium, containing 10% FCS and 20 mM HEPES 
at 37°C under an atmosphere of 5% CO2.
Growth inhibition studies
Growth inhibitory effects of dFdC, Staurosporine and UCN-01 
were evaluated with the sulforhodamine-B (SRB assay) as 
described earlier [21]. Shortly, cells of Lovo variants (5000 
cells/well) were exposed to various drug concentrations 
for 72 hrs. Thereafter, cellular protein was precipitated, 
fixed and stained with SRB and the optical density was 
measured at 540 nm. The interactions were studied at a 
fixed ratio based on the IC50 concentrations of the drugs 
using the multiple drug effect analysis software program 
developed by Chou and Talalay [22], (Calcusyn software, 
BioSoft, Ferguson, MO, 1996) which enables to determine 
drug interactions, given by the Combination Index (CI), in 
which a CI >1.1 represents antagonism, 0.9<CI<1.1 additivity 
and CI<0.9 synergism. CI values are plotted against fraction 
affected (FA) resulting in CI-FA plots; a FA of 0 is normal 
100% growth, FA=0.5 represents the IC50 value and a FA 
of 1 represents 100% growth inhibition. In the CI-FA plot 
the CI values at FA> 0.5 are evaluated and per experiment 
only the CI values at FA 0.5, 0.75 and 0.9 were averaged.
Different treatment schedules were used; simultaneous 
exposure and sequential exposure with dFdC as the first 
drug and PKC inhibitors as the second drug added 24 hr 
after the first drug without refreshing the medium.
FACS analysis
Cell cycle distribution and induction of apoptosis was 
analysed by FACScan (Becton Dickinson, Mount View, CA) 
using Propidium Iodide (PI) as DNA binding agent. After 
drug treatment, adherent and floating cells were harvested 
and counted. After centrifugation (1200 rpm, 5 min), the 
pellet was gently resuspended in 1 ml hypotonic propidium 
iodide (P1)-solution (50 μg/ml Pl, 0.1% sodium citrate, Triton 
X-100, 0.1 mg/ml ribonuclease A) to a concentration of 
5×105–106 cells/ml in round-bottomed fluorescent activated 
cell sorting (FACS) tubes. Cells were analysed by using 
Cellquest software (Becton Dickinson, Mount View, CA). 
Western blot analysis
Frozen cell pellets were lysed in buffer containing 0.1% 
Triton X-100, 150 mM NaCl, 10 mM Tris HCl pH 7.6, and 
5 mM EDTA. Protein content was measured using the 
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BioRad assay. For determination of protein expression, 
25 µg protein was loaded and separated on a 10% SDS-
PAGE gel (acrylamide:bis 29:1), followed by blotting on a 
nitrocellulose membrane. Blocking occurred overnight 
at 4°C with 5% milk powder (Protifar) in TBS-T (TBS (20 
mM Tris pH 7.6 and 150 mM NaCl) mM + 0.05% Tween-20). 
Membranes were incubated for one hr with the primary 
antibodies (dilution 1:100). Subsequently the membranes 
were incubated with HRP conjugated anti mouse or anti-
rabbit antibodies (dilution 1:1000). After each incubation 
step the nitrocellulose membranes were washed several 
times with TBS-T. The HRP was visualized by means of ECL(+) 
detection solution and autoradiography and quantified by 
scanning on a GS-690 Bio-rad scanner (Bio-Rad, Hercules, 
California, USA). Levels of expression were reported relative 
to the untreated control samples [23].
Results
Growth inhibition studies
In order to study the role of p53 mutations on sensitivity 
to and modulation by staurosporine and UCN-01 we used 
three Lovo colon cancer variants (Lovo B2, empty vector 
plasmid control; wild-type p53), Lovo Li (functionally inactive 
p53) and Lovo 175x2 (transfected with mutated p53). Lovo 
175x2 was less sensitive to all three drugs although this 
difference was minor for staurosporine  (Table 1).
The combination indices of dFdC with staurosporine 
or UCN-01 are summarized in Table 2. The simultaneous 
combination of dFdC with UCN-01 was synergistic in 
all Lovo variants. Furthermore,  the highest synergistic 
effect of the combination with UCN-01 was found  in 
mut p53 Lovo 175x2 compared to the other Lovo variants 
(Figure 1). Also for the combination of dFdC with 
staurosporine strong synergism was observed in Lovo 175x2 
but not in Lovo Li cells, while in Lovo B2, the combination 
was not additive. Because exposure to dFdC prior to 
staurosporin or UCN-01 induced more cell death than vice 
versa, we also studied this sequence, by adding staurosporin 
and UCN-01 24 hr after dFdC. The combination with UCN-01 
was also synergistic in Lovo Li and Lovo 175x2 at sequential 
exposure although to a lesser extent than the simultaneous 
combination. However, in Lovo B2 cells the sequential 
combination with UCN-01 even changed to additive and 
that with staurosporin to synergism, while the effects in 
Lovo Li and Lovo175x2 hardly changed. 
Cell cycle analysis
Representative data on cell cycle distribution of 
combinations of dFdC and staurosporin or UCN-01 are 
shown in Figure 2. No clear differences were observed 
between the Lovo variants regarding the effect of the 
drugs on cell cycle distribution. For dFdC (1.0 μM), a gradual 
increase (about 2-fold) of cells in S phase was observed 
in all Lovo variants. Exposure to staurosporine (0.05 μM) 
initially induced accumulation (from 35 to about 60%) of 
cells in the G2/M phase (after 24 hr), which shifted after 
48 hr exposure to the S-phase. An arrest in G0/G1 was 
observed after 24 hr exposure UCN-01 (0.5 μM), while 
IC50 (nM) Lovo B2 Lovo Li Lovo 175x2
Gemcitabine 4 + 1 0.8 + 0.2 22 + 4.8
Staurosporine 3 + 0.6 2 + 0. 6 5 + 0.9
UCN-01 20 + 2 15 + 2.3 91 + 14
Combination Index + SEM
                 Lovo B2                  Lovo Li                         Lovo 175x2
dFdC / UCN (1:1) sim 0.39 + 0.08 +++ 0.47 + 0.11 +++ 0.17 + 0.04 ++++
dFdC -> UCN-01 seq 0.91 + 0.28 + 0.57 + 0.05 +++ 0.45 + 0.15 +++
dFdC/STS (1:1) sim 1.17 + 0.34 - 1.06 + 0.20 + 0.44 + 0.02 +++
dFdC -> STS seq 0.32+ 0.10 +++ 0.87 + 0.28 + 0.53 + 0.26 +++
Table 1. Sensitivity of Lovo variants to gemcitabine, staurosporine and UCN-01. 
Values are means ± SE of at least 3 separate experiments.
Sensitivity to the drugs was determined using the SRB assay with 72-hr exposure.
Table 2. Combination indices for combinations of simultaneous (sim) and sequential (seq) exposure of gemcitabine 
(dFdC) followed by UCN-01 or staurosporine (STS) in Lovo variants
Evaluation of possible synergism using the median drug effect analysis method of Chou and Talalay (Biosoft). CI is given as the mean 
of CI values which represent the synergistic effect calculated for growth inhibition of 50, 75 and 90%. Symbols: ++++ strong synergism, 
+++ synergism, + slight synergism, + nearly additive, - slight antagonism. Results are means + SEM of at least 3 separate experiments.
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after 48 hr cells accumulated in the S phase (up to almost 
2-fold). Simultaneous exposure to dFdC combinations 
showed an average cell cycle distribution of each drug 
alone. In sequentially given drug combinations, the cell 
cycle distribution of the first drug added was dominant. 
Induction of cell death 
Induction of cell death was determined by analysis of the 
sub-G1 fraction of the FACS data. Cell death induction 
was investigated after treatment for 72 hr with dFdC 
combinations (Table 3). In Lovo B2 and Lovo Li cells dFdC 
induced more cell death than in Lovo 175x2. However, in 
Lovo 175x2 cells with mutant p53 UCN-01 and staurosporine 
induced more cell death compared to the other Lovo variants. 
The combination of dFdC with UCN-01 produced more 
cell death in Lovo 175x2 compared to Lovo Li and Lovo B2. 
Figure 1. Representative growth inhibition curves of the simultaneous combination of gem-
citabine (GEM) with UCN-01 in a fixed molar ratio in LovoB2 cells.
Figure 2. Cell cycle distribution of Lovo B2, Lovo Li and Lovo 175x2 after treatment with combinations of 1.0 μM gem-
citabine (dFdC) with 0.5 μM UCN-01 or 0.05 μM STS. Cells were exposed to drugs simultaneously for 24 or 48h (+ bars 
with one time point) or sequentially (STS > dFdC or dFdC > STS; means 48h exposure to the first drug while the last 24 hr 
the second drug was also present. Values are means of 3 separate experiments.
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This is related with the increased induction of cell death 
by UCN-01 in Lovo 175x2 compared with the other Lovo 
variants. A more than additive cell kill of 48 hr exposure by 
dFdC followed by staurosporine or UCN-01 was observed 
in all cell lines. However, the most striking synergistic effect 
was observed in Lovo 175x2. Induction of cell death was 
2-fold higher compared to the additional effect of used 
drugs alone. Furthermore, a more than additive cell kill 
was also observed after treatment of Lovo 175x2 cells with 
simultaneous addition of dFdC and UCN-01.
p53 and E2F protein expression
Since for UCN-01 it has been reported that it may bypass 
P53 dependent cell death we investigated its expression 
in the three lines upon drug exposure. As expected in 
Lovo Li P53 was not induced, while in Lovo 175x2 the high 
expression was not affected (data not shown) . However, 
in Lovo B2 single drug exposure to dFdC upregulated p53 
about 4-fold at 48 hr, but after exposure to STS or UCN-01 a 
slight decrease was found (Figure 3). In simultaneous drug 
exposure, drugs contributed equally to p53 expression 
leading to about 2-fold upregulation. In sequential drug 
exposure, the first drug given dominated in the p53 
induction, leading to no change in p53 expression when 
UCN-01 or STS were added first, although a high extent 
of cell death was found in this sequence. Since also in the 
Lovo 175x2 cells a similar and higher extent of cell death 
was found than in the wt p53, induction of cell death follows 
a p53 independent pathway.
E2F expression showed a differential expression in the 
combinations. In Lovo 175x2 it was only induced in the 
sequential combinations of UCN-01 (Figure 4). For dFdC 
we found a small decrease and for STS a small increase. 
In the STS combinations E2F was decreased when dFdC 
preceded STS. In the Lovo B2 cells UCN-01 and STS increased 
E2F expression. But in the sequential combinations it was 
decreased when dFdC preceded STS or UCN-01.
Discussion
Combinations of dFdC with UCN-01 or staurosporine are 
most effective when cells were exposed to dFdC prior 
to staurosporine or UCN-01. Apparently the cell cycle 
Lovo B2 Lovo Li Lovo 
175x2
Control 1.7 + 1.0 3.1 + 1.5 1.8 + 0.9
24 h dFdC 2.1 + 0.5 4.8 + 1.9 5.9 + 2.1
STS 4.9 + 1.1 5.3 + 2.0 11.2 + 1.7
UCN 5.5 + 1.2 4.7 + 1.9 12.2 + 1.8
STS + dFdC 6.0 + 2.0 9.9 + 3.3 17.3 + 2.5
UCN + dFdC 7.5 + 2.1 7.4 + 2.5 22.2 + 2.3
48 h dFdC 7.3 + 2.2 8.4 + 2.1 4.8 + 1.1
STS 12.2 + 3.5 6.0 + 1.5 15.0 + 3.0
UCN 11.3 + 2.5 12.7 + 1.8 20.1 + 2.5
STS + dFdC 12.2 + 1.9 15.2 + 3.0 16.3 + 1.2
UCN + dFdC 12.7 + 1.8 18.7 + 2.5 29.2 + 2.3
STS > dFdC 13.1 + 3.0 11.3 + 1.8 15.6 + 2.0
UCN >dFdC 10.5 + 2.2 12.0 + 1.7 26.1 + 2.2
dFdC > STS 16.5 + 2.7 17.2 + 2.8 19.5 + 2.1
dFdC > UCN 16.4 + 3.0 20.4 + 2.5 33.1 + 3.1
Cells were exposed to drugs simultaneously for 24 or 48h, 
indicated by + (drug + drug) or sequentially indicated by >, 
this   means 48h exposure to the first drug and the last 24h 
also to the second drug. Values are means + SEM of 3 separate 
experiments and the values are expressed in percentage of cell 
in SubG1 phase (%).
Figure 3. (a) Expression the p53 in Lovo B2 cells after 48h exposure 
of 1.0 μM gemcitabine (gem), 0.5 μM UCN-01 or 0.05 μM staurospo-
rine (STS). Simultaneous exposure (drug + drug) and sequential ex-
posure of drugs were used (drug > drug; the second drug was added 
24 hr after the first drug). The 24 h control (Con) was set on 100%, 
p53 expression was corrected with that of β-actin. (b) representative 
western blot of p53 in untreated Lovo 175x2 cells, and Lovo B2 cells 
treated with several gemcitabine combinations as indicated in (a). All 
samples contained a similar amount of protein and were normalized 
to β-actin. Since in Lovo 175x2 cells treatment did not affect p53 
levels, no treatment samples were shown.
A
B
Table 3. Induction of cell death after treatment of Lovo Li, 
Lovo B2 and Lovo 175x2 with drug combinations of  
gemcitabine (dFdC) (1.0 μM) with UCN-01 (0.5 μM) or  
staurosporine (STS) (0.05 μM).
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effects as induced by the first drug, prevented cells to cycle 
further and cells were forced into apoptosis which was 
most pronounced for the dFdC and UCN-01 combination 
in the cells with mutant p53, in contrast to the other lines. 
Staurosporine and UCN-01 have been developed as protein 
kinase Cα inhibitors, but have multiple other cell cycle 
targeted effects. We demonstrated earlier in non-small 
cell lung cancer cells that potentiation by staurosporine 
is independent of PKC inhibition, but associated with 
a decrease of the cell cycle regulator E2F and an even 
more pronounced decrease of the gemcitabine target 
ribonucleotide reductase [23]. UCN-01 is even less specific 
for PKC and is a known abrogator of cell cycle proteins, such 
as cdk 2 and 4, the G2/M and S checkpoint via “checkpoint 
kinase (chk)” chk1 and possibly chk2. [24]. Hence low 
concentrations of UCN-01 cause S phase arrest progressing 
into the G2 phase before going into apoptosis, while high 
concentrations cause immediate S->M transition [25].
Abrogation of the G2/M checkpoint is an attractive 
target when it is combined with DNA damaging drugs. DNA 
damage triggers the protein kinases ataxia telangiectasia 
(ATM) and ATM-Rad3-related (ATR) to activate chk1 and chk2, 
inactivating the phosphatase cdc25c by phosphorylation, 
which will prevent cyclineB-cdk1 to be dephosphorylated, 
arresting cells in G2-M transition of cells to repair the induced 
DNA damage. In cells with wild-type p53, DNA damage will 
stimulate p53, leading to an S-phase arrest and allowing 
cells to repair DNA damage. In mut-p53 cells this regulation 
is abrogated, so that UCN-01 by inhibition of the G2/M 
checkpoint regulators, will increase DNA damage. Moreover 
UCN-01 will further prevent DNA repair and enhance the 
effect of deoxynucleoside analogues ara-C, dFdC, 5-FU  
[26-31], the purine analogue fludarabine [26,32] and DNA 
binding agents such as cisplatin, thiotepa, mitomycin C, 
cisplatin, melphalan and topotecan [26]. Treatment with 
a DNA damaging drug (cisplatin, 5FU, nucleoside analogs 
or radiation) prior to UCN-01 or a novel ChK1 inhibitor 
(SCH00766) was synergistic and induced more cell death 
than vice versa  through abrogation of the G2/M checkpoint 
and was associated by reduced expression of cyclins A and 
B and activation of Cdk1 [33,34].
UCN-01 and dFdC combinations induced more cell 
death in p53 mutant Lovo 175x2 cells than wt p53 cells.  In 
addition to dFdC this holds for NSCLC cells treated with 
cisplatin or the topoisomerase I inhibitor SN38. In wt p53 
Lovo B2 the induction was additive since UCN-01 led to 
a G1 arrest and in the combination to a decrease in E2F 
and not to the abrogation of the G2/M checkpoint. The 
Figure 4. Expression E2F in Lovo B2 and Lovo 175x2 cells, after 48 h 
exposure of  1.0  μM gemcitabine (gem), 0.5  μM UCN-01 or 0.05  μM 
staurosporine (STS). Simultaneous exposure (drug + drug) and sequential 
exposure of drugs were used (drug > drug; the second drug was added 24 
hr after the first drug). The 24h control (Con) was set on 100%, E2F expres-
sion was corrected with that of b-actin.
Lovo 175X2
Lovo B2
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observation that in cancer cells with inactive p53, post 
treatment with a  checkpoint inhibitor such as UCN-01 
enhanced sensitivity to DNA damaging agents is  an excellent 
approach for combination therapy. Indeed most cancer cells 
have mutations in the G1/S checkpoint (such as the tumor 
suppressor genes p53 and Rb) and only exceptionally cancer 
cells have defects in the G2/M checkpoint.
Kroep et al showed that the activity of dCK is correlated 
with dFdC sensitivity of xenograft mouse models [35]. In 
NSCLC cells treatment with staurosporin increased dCK 
activity, possibly by a mixture of a direct effect [23] or via post-
translational regulation, such as protein phosphorylation. 
Indeed, activation of dCK may involve a phosphorylation-
dependent step, since okadaic acid and calyculin A, broad-
spectrum inhibitors of serine/threonine-specific protein 
phosphatases, significantly increased dCK activities [36,37]. 
In contrast, λ protein phosphatase digestion abolished 
the dCK activity of cell extracts [38]. In addition, Smal et al., 
demonstrated that recombinant; His-tagged dCK can be 
phosphorylated [39]. The synergistic effect of dFdC with 
staurosporin or UCN-01 in colon cancer cells may partly 
be similar to that in NSCLC and due to downregulation of 
free E2F, an upregulation of dCK and a downregulation of 
ribonucleotide reductase. Since UCN-01 clearly interferes 
with cdks, the action of both UCN-01 and staurosporine 
in combination with dFdC seems also to be related to cell 
cycle effects by preventing cells to progress in cell cycle 
after dFdC exposure leading to more cell death.
In conclusion, combinations of dFdC with UCN-01 or 
staurosporine were most effective when cells were exposed 
to dFdC prior to staurosporine or UCN-01. Targeting different 
cell cycle phases and abrogation of cell cycle checkpoints 
are both attractive strategies in combination with DNA 
damaging agents since the sequential combination of DNA 
damaging agents prior to checkpoint abrogators such as 
UCN-01 and novel analogs, prevent repair of DNA damage 
leading to cell death.
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